Search Results

You are looking at 1 - 10 of 35 items for :

  • "GH deficiency" x
Clear All
Open access

Taísa A R Vicente, Ívina E S Rocha, Roberto Salvatori, Carla R P Oliveira, Rossana M C Pereira, Anita H O Souza, Viviane C Campos, Elenilde G Santos, Rachel D C Araújo Diniz, Eugênia H O Valença, Carlos C Epitácio-Pereira, Mario C P Oliveira, Andrea Mari and Manuel H Aguiar-Oliveira

. ( doi:10.1210/jc.84.3.917 ). 10 Aguiar-Oliveira MH Gill MS de A Barretto ES Alcântara MR Miraki-Moud F Menezes CA Souza AH Martinelli CE Pereira FA Salvatori R . Effect of severe growth hormone (GH) deficiency due to a mutation

Open access

Guillem Cuatrecasas, Hatice Kumru, M Josep Coves and Joan Vidal

( 3 ). Some case report was published ( 7 ) and the work done in transitional rodent models ( 8 , 9 , 10 ) focused our attention on the potential of GH for neurologic improvement in SCI. However, in humans, very little is known about GH deficiency in

Open access

Rachel D C A Diniz, Renata M Souza, Roberto Salvatori, Alex Franca, Elenilde Gomes-Santos, Thiago O Ferrão, Carla R P Oliveira, João A M Santana, Francisco A Pereira, Rita A A Barbosa, Anita H O Souza, Rossana M C Pereira, Alécia A Oliveira-Santos, Allysson M P Silva, Francisco J Santana-Júnior, Eugênia H O Valença, Viviane C Campos and Manuel H Aguiar-Oliveira

hepatocellular carcinoma is higher than 10% in 5 years (6) . It is therefore important to define the causes of NAFLD. Adult-onset GH deficiency (AOGHD) constitutes a specific model of metabolic syndrome (7, 8) , with visceral obesity, insulin resistance

Open access

Ursula M M Costa, Carla R P Oliveira, Roberto Salvatori, José A S Barreto-Filho, Viviane C Campos, Francielle T Oliveira, Ivina E S Rocha, Joselina L M Oliveira, Wersley A Silva and Manuel H Aguiar-Oliveira

synergistic anabolic effect on muscle mass, but antagonist effects on insulin action (GH-reducing and IGF1 increasing insulin sensitivity) and lipolysis (GH increasing and IGF1 reducing it) (2) . Adult onset GH deficiency (GHD) has been described as model of

Open access

Charlotte Höybye, Erik Wahlström, Petra Tollet-Egnell and Gunnar Norstedt

individuals. The metabolic and anthropometric characteristics of the controls are given in Table 2 . Table 2 Metabolic and anthropometric characteristics (mean± s.d. ) of ten healthy controls and ten patients with growth hormone (GH) deficiency at baseline

Open access

Pinaki Dutta, Bhuvanesh Mahendran, K Shrinivas Reddy, Jasmina Ahluwalia, Kim Vaiphei, Rakesh K Kochhar, Prakamya Gupta, Anand Srinivasan, Mahesh Prakash, Kanchan Kumar Mukherjee, Viral N Shah, Girish Parthan and Anil Bhansali

(QoL) (1) . However, successful treatment of acromegaly either by surgery, radiation or combinations of different treatment modalities results in GH deficiency (GHD) in nearly 30–60% of patients (2, 3) . The prevalence of GHD increases as the duration

Open access

Charlotte Höybye, Andreas F H Pfeiffer, Diego Ferone, Jens Sandahl Christiansen, David Gilfoyle, Eva Dam Christoffersen, Eva Mortensen, Jonathan A Leff and Michael Beckert

compared to Omnitrope at equivalent weekly dosing. IGF1 exposure after equivalent dosing of TransCon GH and Omnitrope was also similar. AGHD is associated with increased mortality, mainly due to cardiovascular risk. GH deficiency contributes to visceral

Open access

Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen and on behalf of the Growth Hormone Research Society

factor-I (IGF-I). Both are used diagnostically; IGF-I is used to monitor the effects of GH replacement in GH deficiency (GHD), and both GH and IGF-I are used in the diagnosis and management of acromegaly. While serum IGF-I level is used as a surrogate

Open access

Sheila Leone, Lucia Recinella, Annalisa Chiavaroli, Claudio Ferrante, Giustino Orlando, Michele Vacca, Roberto Salvatori and Luigi Brunetti

lack the decline in cognitive ability in the Morris water maze test that is observed in WT mice ( 9 , 10 ). GHRHKO mice represent an animal model of isolated GH deficiency with otherwise normal pituitary function ( 11 ). We have recently demonstrated

Open access

Ekaterina Koledova, George Stoyanov, Leroy Ovbude and Peter S W Davies


The easypod connect observational study (ECOS) assessed treatment adherence among paediatric patients receiving growth hormone (GH) via the easypod electronic injection device.


ECOS was an open-label, observational, longitudinal study conducted in 24 countries between 2010 and 2016, enrolling children treated with GH.


The primary endpoint was the rate of treatment adherence during 5 years of follow-up. Impact of adherence on growth outcomes was assessed using Spearman’s product–moment correlations.

Results and conclusions

Overall, 1190 patients had easypod data available for ≥3 months; most patients had GH deficiency (75%); 606 of these patients were GH naïve at baseline. Over the first year of monitoring, the median rate of adherence was 93.7% among patients overall and >93.0% in GH-naïve patients, irrespective of the treatment indication. Clinically meaningful improvements in growth rates were observed after 1 year of treatment across all GH indications. Adherence decreased with increasing treatment duration, but the overall median adherence rate remained high after 3 years of follow-up: 87.2% (n = 409), 75.5% after 4 years (n = 143) and 70.2% after 5 years (n = 43). Statistically significant correlations between adherence and 1-year change in height standard deviation score (P < 0.001 for patients overall) and height velocity (P < 0.001) were observed.


ECOS produced accurate, real-time adherence data in a large population of GH-treated children over 5 years of follow-up. Using the easypod connect system, physicians can potentially identify patients with inadequate adherence and poor response to treatment, enabling them to take appropriate action to help them maximise the benefits of GH treatment.